Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Dendreon Corporation    DNDN   US24823Q1076

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/12/2014 11/13/2014 11/14/2014 11/17/2014 11/18/2014 Date
0.161(c) 0.1278(c) 0.1122(c) 0.147(c) 0.127(c) Last
17 187 590 18 661 437 13 200 437 26 465 112 22 715 168 Volume
+7.19% -20.62% -12.21% +31.02% -13.61% Change
More quotes
Company
Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients.The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular... 
Sector
Biotechnology & Medical Research
Calendar
01/26 | 12:40pmPresentation
More about the company
Surperformance© ratings of Dendreon Corporation
Trading Rating : Investor Rating :
More Ratings
Chart DENDREON CORPORATION
Duration : Period :
Dendreon Corporation Technical Analysis Chart | DNDN | US24823Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 297 M
EBIT 2014 -57,0 M
Net income 2014 -107 M
Debt 2014 -
Yield 2014 -
Sales 2015 317 M
EBIT 2015 -20,8 M
Net income 2015 -73,1 M
Debt 2015 421 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 0,08x
EV / Sales 2015 1,40x
Capitalization 24,1 M
More Financials
Latest news on DENDREON CORPORATION
01/23 DENDREON : Announces Strong Commercial Start to 2015
01/22 DENDREON : Other Events (form 8-K)
01/22 DENDREON : Results of Operations and Financial Condition, Financial Statements a..
01/22 DENDREON : Cites Strong Commercial Start to 2015
01/21 DENDREON : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
01/19 DENDREON : Cites Strong Commercial Start to 2015
01/15 DENDREON : Announces Strong Commercial Start to 2015
01/12 DENDREON : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
More news
Sector news Biotechnology & Medical Research - NEC
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 QUINTILES TRANSNATIONAL : Investigator Initiated Trials is Topic of New Handbook..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF